San Diego-based BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage oncology company whose lead program targets a form of EGFR-mutant lung cancer with no approved oral therapy, filed an amended S-1 registration statement with the US Securities and Exchange Commission on August 3, 2026, setting terms for an IPO that would raise approximately USD 125 million at a midpoint price of USD 16.00 per share.
The company plans to offer 7.8 million shares at a proposed price range centered on USD 16.00 per share, raising approximately USD 125 million before underwriters' options. BlossomHill intends to list on the Nasdaq Global Select Market under the ticker "BLSM."
BlossomHill raised over USD 257 million in pre-IPO capital, the filing states, including a USD 100 million Series B round closed in 2024 and an USD 84.2 million Series B bridge round closed in December 2025. Janus Henderson Investors, a public-market asset manager, led the bridge round with approximately USD 20 million. Cormorant Asset Management and OrbiMed, which hold 15.5% and 9.8% of pre-IPO shares respectively, participated in both rounds.
The company intends to use net proceeds to advance the Phase I/II SOLARA trial of BH-30643 and initiate a planned registrational Phase II trial, continue the Phase I trial of BH-30236, and complete IND-enabling studies for BH-501284, with the remainder for general corporate purposes.
BlossomHill was founded in 2020 by J. Jean Cui, Ph.D., the lead inventor of three FDA-approved cancer therapies — crizotinib (Xalkori), lorlatinib (Lorbrena), and repotrectinib (Augtyro) — and co-founder of Turning Point Therapeutics, which Bristol Myers Squibb acquired in 2022. Co-Founder and Executive Chairman Y. Peter Li, Ph.D., previously led Turning Point through its 2019 IPO. Chief Medical Officer Geoffrey R. Oxnard, M.D., co-authored the first published description of the EGFR C797S resistance mutation that BH-30643 is designed to overcome.
The lead asset, BH-30643, is a non-covalent, macrocyclic OMNI-EGFR inhibitor being evaluated in the global SOLARA Phase I/II trial in patients with EGFR-mutant non-small cell lung cancer (NSCLC), including those with C797S-mediated resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) — a population for which no approved oral targeted therapy currently exists, the filing states. The company plans to seek an end-of-Phase I meeting with the FDA in Q4 2026 regarding a potential accelerated approval pathway in C797S-positive EGFR-mutant NSCLC, and expects to dose the first patient in a registrational Phase II trial in Q1 2027.